Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROPHESYS-1
- Sponsors Roche
- 09 May 2016 Time frame of the primary end point changed from weeks 4 and 12, and 24 weeks after EOT to At 24 weeks after EOT.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Nov 2011 Planned end date changed from 1 Nov 2010 to 1 Feb 2012 as reported by ClinicalTrials.gov.